Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
Volume 0.06M
Average 0.44M
ENLV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Enlivex Therapeutics Ltd.NASDAQ: ENLV
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $3.03M fell 11.4% year over year, ahead of the -13.4% change in trailing-twelve-month research & development. Sequentially, it rose 104.1% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -11.4% holds above the trailing-twelve-month pace of -13.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 8.92M USD
- Year-over-year change
- -11.9%
- 4-year CAGR
- -8.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.92M | -11.9% |
| FY2024 | 2024-12-31 | 10.13M | -47.4% |
| FY2023 | 2023-12-31 | 19.24M | +2.9% |
| FY2022 | 2022-12-31 | 18.69M | +45.1% |
| FY2021 | 2021-12-31 | 12.88M | — |
Research & Development vs competitors
How ENLV compares with its peers on the latest reported figures
- ENLV's LTM Dec 2025 research & development of $9.2M is the highest of the 2 companies compared; the peer median is $532.62K.
- Its year-over-year change of -13.4% is the lowest of 2, against a peer median of +104.0%.
- Over three fiscal years its annual growth of -21.9% compares with a peer median of +29.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $9.2M | -13.4% | -21.9% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | $532.62K | +104.0% | +29.8% | 12.4% |
| Peer median (excluding ENLV) | $532.62K | +104.0% | +29.8% | 12.4% | |
Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 546K | 777K | 835K | 545K | 332K |
| Gross Profit | (546K) | (777K) | (835K) | (545K) | (332K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.88M | 18.69M | 19.24M | 10.13M | 8.92M |
| Selling, General & Admin | 6.24M | 6.7M | 6.14M | 4.91M | 5.69M |
| Operating Expenses | 19.29M | 25.8M | 29.4M | 14.99M | 14.67M |
| Depreciation & Amortization | 546K | 777K | 835K | 545K | 332K |
| EBITDA | (18.74M) | (25.02M) | (28.22M) | (14.47M) | (14.67M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.29M) | (25.8M) | (29.4M) | (15.54M) | (15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 120K | 835K | 1.57M | 1.07M | 792K |
| Interest Expense | 328K | 5.26M | 14K | 13K | 13K |
| Other Income / Expenses | 4.82M | (5.26M) | 327K | 522K | 1.63B |
| Income Before Tax | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.62B |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 382.65M |
| Net Income | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.24B |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (8.10) | (34.65) | (23.40) | (10.95) | 405.60 |
| EPS (Diluted) | (8.10) | (34.65) | (23.40) | (10.95) | 382.20 |
| Weighted Avg Shares | 1.19M | 1.23M | 1.24M | 1.37M | 3.05M |
| Weighted Avg Shares (Diluted) | 1.19M | 1.23M | 1.24M | 1.37M | 3.23M |
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
Intrinsic Alpha fair value
Locked
Current Price
$4.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.